In AML bortezomib decreased Sp1 transcription factor (Sp1) protein levels and interfered with Sp1/NF-κB complex, leading to DNMT1 downregulation and transcription of methylation-silenced genes. Here, SP1 is linked to acute myeloid leukemia.